| 奎泰和舒普深治疗成人下呼吸道感染的药物经济学分析 |
| |
| 引用本文： | 程秀琴. 奎泰和舒普深治疗成人下呼吸道感染的药物经济学分析[J]. 安徽医药, 2004, 8(5): 375-376 |
| |
| 作者姓名： | 程秀琴 |
| |
| 作者单位： | 安徽省肺科医院,安徽,合肥,230022 |
| |
| 摘 要： | 目的探讨不同抗生素治疗下呼吸道感染的经济效果.方法抽取本院59例下呼吸道感染者,分为两组,分别给予奎泰与舒普深进行治疗,运用药物经济学费用-效果分析方法进行评价.结果奎泰组和舒普深组方案总成本分别为1 764.00元和3 133.20元,其效果分别为86.20%和93.33%.每增加一个单位效果奎泰组较舒普深组节省192.00元.结论奎泰组的治疗方案为下呼吸道感染治疗的较佳方案.
|
| 关 键 词： | 奎泰 舒普深 下呼吸道感染 费用-效果分析 |
| 文章编号： | 1009-6469(2004)05-0375-02 |
| 修稿时间： | 2004-01-12 |
Pharmacoeconomic analysis of gatifloxacin vs sulperazon in treatment of lower respiratory tract infections in adults |
| |
| CHENG Xiu qin. Pharmacoeconomic analysis of gatifloxacin vs sulperazon in treatment of lower respiratory tract infections in adults[J]. Anhui Medical and Pharmaceutical Journal, 2004, 8(5): 375-376 |
| |
| Authors: | CHENG Xiu qin |
| |
| Abstract: | Aim To discuss the economic efficiency of different antimicrobials in treatment of lower respiratory tract infections(LRTI).Methods 59 cases of LRTI collected from this hospital were divided into two groups,one group received gatifloxalin and the other received sulperazon.Evaluation was carriend out with pharmacoeconomic cost effectiveness analysis.Results The total costs were 1 764 00 yuans and 3 133 20 yuans and the effective rates were 86 20 % and 93 33% in group gatiflaxacin and sulperazon respectively. An increase of 1% effective rate in group gatifloxacin save 192 00 yuans in comparison with that in group sulperazon.Conclusion The therapeutic scheme of pefloxacin seems to be the best one for treating LRTI. |
| |
| Keywords: | gatifloxacin sulperazon lower respiratory tract infection cost effectiveness analysis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
